Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2023
Clinical studies: you can see better with the second arm
6 October 2023 - In a statement to the EMA, the IQWiG emphasised that single-arm studies may be sufficient for ...
Posted by Michael Wonder on 02 Mar 2023
Efficient RCTs with real world data for benefit assessments: accelerating evidence-based care
2 March 2023 - Together with colleagues from the Belgian HTA agency KCE, three employees of IQWiG in the BMJ are ...
Posted by Michael Wonder on 19 Sep 2022
Registry-based randomised trials: the best of both worlds?
15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...
Posted by Michael Wonder on 03 Mar 2022
Criticism of study planning: patient-reported endpoints are often collected far too briefly
3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side ...
Posted by Michael Wonder on 02 Dec 2021
Call for a central portal for clinical study reports
1 December 2021 - In an open-access publication in the Journal of European CME, two authors from IQWiG argue that ...
Posted by Michael Wonder on 22 Feb 2021
Clinical relevance of patient-reported outcomes: new threshold proves to be practical
18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses ...
Posted by Michael Wonder on 14 Dec 2020
From publication bias to lost in information
11 December 2020 - In BMJ Evidence-Based Medicine, IQWiG researchers call for a central, public and worldwide portal for clinical ...
Posted by Michael Wonder on 14 Jun 2018
Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany
13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...
Posted by Michael Wonder on 16 Jan 2018
Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...
Posted by Michael Wonder on 15 Jan 2018
German watchdog calls for direct comparison of cancer immunotherapies
16 January 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising ...
Posted by Michael Wonder on 09 Jan 2018
Finding RCTs of new drugs: searches in trial registries require specific adaptations
5 January 2018 - In their article in the Journal of Clinical Epidemiology, Marco Knelangen, Elke Hausner, Sibylle Sturtz, and ...
Posted by Michael Wonder on 16 Aug 2016
German agency criticizes European program for speeding some drug approvals
15 August 2016 - in pointed remarks, Germany’s cost-effectiveness watchdog has criticized an effort by European regulators to accelerate approval ...
Posted by Michael Wonder on 09 Aug 2016
Adaptive pathways: EMA still leaves open questions unanswered
9 August 2016 - Current EMA report on the pilot project again documents perplexity regarding the use of “real world data”. ...